'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).

Pao W, Miller VA, Kris MG
Semin Cancer Biol. 2004 14 (1): 33-40

PMID: 14757534 · DOI:10.1016/j.semcancer.2003.11.005

Gefitinib (ZD1839, Iressa), a selective drug inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK), was recently approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC). This article reviews the identification of EGFR as a therapeutic target and the steps in the development of gefitinib as "targeted" monotherapy for patients with NSCLC. Whether EGFR is required for the maintenance of lung tumor survival is also discussed. Finally, strategies to identify predictors of response to gefitinib are explored.

MeSH Terms (8)

Animals Carcinoma, Non-Small-Cell Lung Clinical Trials as Topic ErbB Receptors Gefitinib Humans Lung Neoplasms Quinazolines

Connections (1)

This publication is referenced by other Labnodes entities: